⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282602 | 1.00 | — | — | |
| SCHEMBL8217149 | 1.00 | — | — | |
| SCHEMBL24205845 | 0.81 | — | — | |
| SCHEMBL21345876 | 0.81 | — | — | |
| SCHEMBL13175735 | 0.81 | — | — | |
| SCHEMBL23157074 | 0.81 | — | — | |
| SCHEMBL16359889 | 0.81 | — | — | |
| SCHEMBL7327299 | 0.80 | SLC7A5 (0.52) | — | |
| SCHEMBL23762426 | 0.79 | DPP4 (0.47) | — | |
| SCHEMBL13322716 | 0.79 | DPP4 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11541049-B2 | Tetrahydroisoquinoline derivatives, preparation process and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20210052576-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| WO-2020247540-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20190284149-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2017210566-A1 | POLYMER LINKERS AND THEIR USES | NOVACYTE, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| WO-2013036567-A2 | METHODS, COMPOSITIONS, AND COMPOUNDS FOR THE REDUCTION OF ILLEGAL METHAMPHETAMINE PRODUCTION | JOHNSON BRENT A (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2010132538-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20090238790-A2 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | disclosed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | disclosed |
| WO-2007001926-A2 | LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR | HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-0621270-B1 | Piperazine derivatives as collagenase inhibitors | SANKYO CO (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5643908-A | ANGIOGENESIS INHIBITOR, ANTITUMOR | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0621270-A1 | COLLAGENASE INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1994-10-26 | — | — | EP | disclosed |